Loading...
XPAR
VLA
Market cap263mUSD
Jun 04, Last price  
2.76EUR
1D
-1.42%
1Q
-15.03%
Jan 2017
-10.36%
IPO
-71.49%
Name

Valneva SE

Chart & Performance

D1W1MN
P/E
P/S
1.38
EPS
Div Yield, %
Shrs. gr., 5y
9.69%
Rev. gr., 5y
6.09%
Revenues
170m
+10.32%
3,011,0002,329,000866,0003,418,0003,096,0008,395,00010,263,0003,431,00030,445,00036,923,00078,359,00094,062,000105,291,000113,035,000126,196,000110,321,000348,085,000361,303,000153,712,000169,578,000
Net income
-12m
L-87.93%
-1,220,000-243,000-3,362,000-2,389,000-6,144,000-7,962,000-4,419,000-12,985,000-23,973,000-26,272,000-20,617,000-49,184,000-11,482,0003,264,000-1,744,000-64,393,000-73,425,000-143,279,000-101,429,000-12,247,000
CFO
-67m
L-66.85%
681,000-2,735,000-3,565,000-1,842,000939,000-3,154,000-8,656,000-13,220,000-20,903,000-14,944,000-24,334,0006,505,00012,829,00016,306,0005,529,000137,738,00076,901,000-245,343,000-202,744,000-67,218,000
Earnings
Aug 11, 2025

Profile

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
IPO date
Jun 28, 2007
Employees
719
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
169,578
10.32%
153,712
-57.46%
361,303
3.80%
Cost of revenue
267,787
257,320
486,945
Unusual Expense (Income)
NOPBT
(98,209)
(103,608)
(125,642)
NOPBT Margin
Operating Taxes
761
2,800
1,536
Tax Rate
NOPAT
(98,970)
(106,408)
(127,178)
Net income
(12,247)
-87.93%
(101,429)
-29.21%
(143,279)
95.14%
Dividends
Dividend yield
Proceeds from repurchase of equity
(240)
189,837
BB yield
0.07%
-25.85%
Debt
Debt current
23,360
46,958
36,991
Long-term debt
221,893
193,827
168,964
Deferred revenue
Other long-term liabilities
7,085
11,094
8,070
Net debt
76,983
114,705
(83,475)
Cash flow
Cash from operating activities
(67,218)
(202,744)
(245,343)
CAPEX
(13,865)
(14,231)
(29,322)
Cash from investing activities
76,916
(20,585)
(29,054)
Cash from financing activities
30,682
63,081
215,116
FCF
(122,640)
(134,431)
(107,385)
Balance
Cash
168,270
126,080
289,430
Long term investments
Excess cash
159,791
118,394
271,365
Stockholders' equity
(499,399)
(465,111)
(374,246)
Invested Capital
904,050
813,268
738,224
ROIC
ROCE
EV
Common stock shares outstanding
145,706
69,312
115,474
Price
2.19
-57.84%
5.18
-18.48%
6.36
-77.09%
Market cap
318,513
-11.36%
359,349
-51.07%
734,414
-72.89%
EV
395,496
474,054
650,939
EBITDA
(78,623)
(86,024)
(104,606)
EV/EBITDA
Interest
23,984
23,325
19,054
Interest/NOPBT